Innate Pharma (IPHA) Operating Income (2020 - 2025)

Innate Pharma (IPHA) has 5 years of Operating Income data on file, last reported at -$28.8 million in Q2 2025.

• For the quarter ending Q2 2025, Operating Income fell 1.57% year-over-year to -$28.8 million; the trailing twelve-month figure through Jun 2025 stood at -$112.3 million (down 47.8% YoY), and the FY2025 full-year result was -$62.9 million, down 14.07% from the prior year.
• Operating Income for Q2 2025 stood at -$28.8 million, down from -$28.3 million in the prior quarter.
• Across five years, Operating Income topped out at $7.5 million in Q2 2021 and bottomed at -$54.7 million in Q4 2021.
• The 4-year median for Operating Income is -$28.3 million (2024), against an average of -$20.9 million.
• The widest annual swing landed in 2021, when Operating Income jumped 181.84%; it then sank 6438.23% in 2024.
• A 4-year view of Operating Income shows it stood at -$54.7 million in 2021, then jumped by 99.21% to -$433391.9 in 2023, then tumbled by 6438.23% to -$28.3 million in 2024, then decreased by 1.57% to -$28.8 million in 2025.
• The last three Operating Income figures came in at -$28.8 million (Q2 2025), -$28.3 million (Q2 2024), and -$433391.9 (Q2 2023), per Business Quant data.

Peer Comparison